AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03274440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: THC and CBD are cannabinoids which are found naturally in the marijuana plant. Both act on the brain's endocannabinoid system, which has been hypothesized to play a role in OCD.
Study NCT03274440 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control group, not receiving THC or CBD.
Study NCT02234089 — intervention group
Intervention type: DRUG
Intervention: Degarelix
Description: According to medical practice
Study NCT02234089 — intervention group
Intervention type: DRUG
Intervention: LHRH agonist (Leuprorelinacetat, Goserelinacetat, Buserelinacetat, Triptorelinacetat)
Description: According to medical practice
Study NCT02759471 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A sphere lens (control)
Description: contact lens
Study NCT02759471 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comfilcon A asphere lens (test)
Description: contact lens
Study NCT01125683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1446
Description: Capsule, oral single and multiple dose
Study NCT01125683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: Capsule, oral and single dose
Study NCT01125683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, oral and single dose
Study NCT01442493 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-Centered Methadone Treatment
Description: Unlike in treatment as usual, counseling will be encouraged but not required and counselors will be responsible for enforcing the clinic's rules. The rules will be enforced by the Clinical Director. Clinic rules will be modified such that involuntary discharge from treatment will be a rare event.
Study NCT01442493 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Methadone Treatment as usual
Description: Counseling will be required and counselors will enforce the usual clinic rules. Involuntary discharge may occur for ongoing drug use or rule infractions as usually occurs in the clinic.
Study NCT03853850 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone text messages
Description: From their babies' day of birth until 6 months of age, participating mothers will receive supportive and educational text messages to promote breastfeeding. Messages will be on benefits of breastfeeding, newborn hunger cues, proper latch technique, healthy infant feeding practice, and maternal self care. Messages will be sent regularly, initially several messages every day during the babies' first few weeks of life, then few messages every week. A total of 158 (\*\*\*) messages will be sent. Messages will be sent in English or in Spanish depending on participant language preference.
Study NCT01781793 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Room air
Description: Humidified room air (21% oxygen) will be inspired
Study NCT01781793 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperoxia
Description: 60% oxygen will be inspired
Study NCT00678938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking abstinence oriented expert system intervention
Description: Participants received up to three counselling letters targeting smoking cessation
Study NCT00678938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking reduction oriented expert system intervention
Description: Participants received up to three counselling letters targeting smoking reduction
Study NCT01350752 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RDTs & Provider Training on Malaria Diagnosis and Treatment
Description: In Cameroon and Nigeria, malaria RDTs will be made available in health facilities and health care providers will receive training and job aids on malaria diagnosis and treatment. The training course covers the following topics: clinical and parasitological diagnosis of malaria, how to use a rapid diagnostic test, algorithm based on malaria test result, recommended treatment for confirmed malaria cases (including dosage and regimen for artemisinin-based combination therapies), advice for treatment of test-negative patients
Study NCT01350752 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Extended provider training (Cameroon only)
Description: 2-day training course which supplements basic provider training on malaria diagnosis and treatment, which focuses on understanding change in malaria treatment guidelines, professionalism, and communication skills
Study NCT01350752 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: School based malaria education (Nigeria only)
Description: Schools will be invited to undertake activities to raise awareness about malaria RDTs and treatment among children and community members. The intervention includes training teachers on peer health education, malaria awareness activities and providing support to hold a malaria educational event
Study NCT03783000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: Treatment T
Study NCT03783000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 mixed with [C-14]-BI 425809
Description: Treatment R
Study NCT04149470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 20mg BID
Description: High dose PPI therapy (Omeprazole 20mg twice daily)
Study NCT01235845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological: DC activated CIK combined with DC
Description: Dendritic cells pulsed With tumor lysate were injected back into the patient intradermally close to a lymph node, DC vaccinations will be given every week for a total of four vaccinations.~DC activated CIK combined with IL-2 were injected intratumorally via an Ommaya reservoir every week for a total of two vaccinations.
Study NCT02340247 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Study NCT02340247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid
Study NCT02340247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic Acid
Study NCT03825146 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Multi-lineage Potential Cells (AMPC)
Description: Multi-lineage potential cells which were induced to de-differentiate from somatic leukocytes from peripheral blood. Cells are autologous with respect to the patient, and are prepared in a suspension and administered via intravenous infusion.~An estimated average of 1 x 10\^8 (0.5 to 5.0 x 10\^8) cells/per suspension(275 to 450mL) will be infused into the patient via intravenous infusion on day 5. Cell counts depend on yield of initial leukocyte harvest on day 0.
Study NCT03213743 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine Injection
Description: Investigators gave the patients loading dose of dexmedetomidine for 10 minutes and maintaining dose of dexmedetomidine for 20 minutes. Investigators took blood samples before and after the administration of dexmedetomidine.
Study NCT02251704 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling
Description: Capillary blood samples collected by finger/heel prick for determination of parasite prevalence at the time of survey.
Study NCT02251704 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Assessment of body temperature
Description: Axillary body temperature of all subjects recorded by a digital thermometer at the time of survey.
Study NCT01247025 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This study will not contain a specific intervention
Study NCT00825942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-KAD Ophthalmic Solution
Description: 4 drops applied daily for 180 days
Study NCT00504933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bilastine
Description: 20 mg (encapsulated) tablets QD/14days
Study NCT02072499 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: KTP Green Light Prostatectomy
Study NCT02072499 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Green Light
Study NCT02072499 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open prostatectomy
Study NCT02806570 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mitral valve repair
Study NCT03769415 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrinsic Subtyping of Primary Breast Cancer
Description: Primary breast tissue will be sent for Nanostring PAM50 Testing to determine intrinsic subtype
Study NCT03736720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT03736720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV
Study NCT03736720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Irinotecan
Description: Given IV
Study NCT03736720 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Correlative studies
Study NCT04030130 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NDURE
Description: NDURE is a theory-based, multi-level Patient Navigation (PN) intervention consisting of three in-person, clinic-based sessions of manualized PN with multiple intervention components that target system- (care coordination), interpersonal- (social support), and individual- (Health Belief Model; perceived susceptibility, severity, barriers, self-efficacy) level health behavior theoretical constructs to reduce barriers to care, improve cancer care delivery, and improve clinical outcomes (timely, equitable PORT). NDURE will be delivered from surgical consultation to PORT initiation (\~3 months).
Study NCT03065335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: N-methyl-D-aspartate (NMDA) glutamate receptor (NMDA-R) antagonist
Study NCT03065335 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT00504933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine
Description: 10 mg (encapsulated) tablets. QD/14 days
Study NCT03065335 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cobot TS MV robotic arm for TMS
Description: TMS-Cobot TS MV \[Axilum Robotics\] robotic arm for spatial positioning and orientation of the TMS coil
Study NCT02428998 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng
Study NCT02428998 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00853242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03065335 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cobot TS MV robotic arm for TMS
Description: TMS-Cobot TS MV \[Axilum Robotics\] robotic arm for spatial positioning and orientation of the TMS coil
Study NCT03065335 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeurOptics PLRTM-30000 Pupillometer
Description: The Neu-rOptics PLRTM-3000 Pupillometer will use quantitative infrared technology to objectively and accurately measure pupil size and dynamics.
Study NCT00504933 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: (encapsulated) Tablets QD/14 days
Study NCT00938639 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL425
Description: CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume)
Study NCT04876274 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TMU-LOVE
Description: Patients in intervention group could attend diabetes-related health educational video through the TMU-LOVE platform. Researcher would also send 2-3 videos per week with care massage every 2 weeks to the patients.
Study NCT02051608 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received Placebo SC injection Q4W.
Study NCT04318366 — intervention group
Intervention type: OTHER
Intervention: Observational Study
Description: Not required
Study NCT00853242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genz-644470
Study NCT02051608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gantenerumab
Description: Participants received Gantenerumab at 105 mg , 225 mg, or at doses up to 1200 mg SC injection Q4W.
Study NCT01573572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaptanib sodium injection
Description: 0.3mg of Macugen in a single-use, prefilled glass syringe given every 6 weeks for 48 weeks
Study NCT06801873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endotoxin (E. coli O:113, Reference Endotoxin)
Description: Intravenous administration of 2 ng/kg endotoxin. This is a non-investigational product. Endotoxin is used as challenge agent to achieve a controlled inflammatory state.
Study NCT00853242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer carbonate
Study NCT00867802 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction program
Description: Mindfulness- Based Stress Reduction comprising of 8 classes and a one-day retreat, taught over a period of 6 weeks. Intervention also includes practice at home for 20-30 minutes.
Study NCT01683747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Study NCT01683747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control Intervention (Carrier fluid only)
Study NCT01164891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5185426
Description: Continuous oral dosing b.i.d. , on Day 15 a C isotope labeled dose will be administered
Study NCT03883919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: -Standard of care drug
Study NCT03883919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: -Standard of care drug
Study NCT03883919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Irinotecan
Description: -Standard of care drug
Study NCT03883919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: -Investigational drug
Study NCT03883919 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serum and plasma blood samples
Description: -baseline, day 1 of each cycle beginning with cycle 2
Study NCT03883919 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Description: * 5 patients in each arm will be required to undergo a mandatory tumor biopsy from the primary pancreatic site or metastatic site, if safe and feasible, prior to cycle 1~* After Cycle 3 of treatment, all patients who had a baseline biopsy will be required to undergo a mandatory biopsy of the same site if safe and feasible.
Study NCT00338286 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard supportive care (packed RBC transfusion)
Description: Per doctor prescription
Study NCT00338286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epoetin alfa + packed RBC transfusion
Description: 40,000 IU SC once a week.
Study NCT06801782 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Cognitive training in Immersive Virtual Reality and Telemedicine approach
Description: The cognitive training involved a 4-week immersive virtual reality program to improve planning, cognitive flexibility, and information updating in patients with mild cognitive impairment related to Parkinson's disease. Over 12 sessions of 30 minutes each, participants trained in a virtual supermarket to strengthen attentional and executive skills. The planning task required creating and following a route to collect items while following rules, with increasing complexity. The cognitive flexibility task involved alternating between selecting items from different categories, with difficulty rising due to more categories and distractors. The updating task, set at a virtual checkout, challenged participants to memorize and recall items on a conveyor belt, with difficulty increasing based on sequence length and item count. Progression to higher levels required three successful trials, with feedback provided to support performance improvement
Study NCT06801782 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator #1
Description: The active placebo used the same virtual environment, Oculus Go system, and telemedicine setup as the training group, but engaged in tasks with low cognitive demands, mimicking everyday activities. The placebo-planning task involved following a fixed shopping list order in a modified version of the Zoo Map Test. The placebo-shifting task required selecting items from shelves without alternating between categories, while the placebo-updating task involved recalling only the last item from a conveyor belt sequence. The sessions mirrored the training group's structure, with 12 sessions over 4 weeks (3 per week, 30 minutes each), maintaining the same frequency, duration, and levels than Training.
Study NCT04579731 — intervention group
Intervention type: DRUG
Intervention: Lactitol Monohydrate
Description: Patients with lower urinary tract dysfunction and assumed to have constipation were placed on lactitol monohydrate 10 g for 8 weeks, and had re-evaluated.
Study NCT00489541 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation
Description: TAXUS Element stent implantation
Study NCT03132207 — intervention group
Intervention type: OTHER
Intervention: Non interventionel study
Description: Only one questionnaire will be done for women and professional
Study NCT00755144 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LCS Knee
Description: Cementless total knee arthroplasty with LCS Knee
Study NCT00755144 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ROCC Knee
Description: Cementless total knee arthroplasty with ROCC Knee
Study NCT01870830 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Altitude exposure
Description: Stay at different altitudes: 490, 1650, 2590 m
Study NCT03582566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phonological Awareness
Description: Earobics training
Study NCT03582566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working Memory
Description: Cogmed training
Study NCT03582566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phonological Awareness + Working Memory
Description: Earobics + Cogmed training
Study NCT03582566 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Spashmath
Study NCT01645046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme A
Description: Coenzyme A 200mg per day.
Study NCT01645046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme A
Description: Coenzyme A 400mg per day.
Study NCT01645046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule without coenzyme A.
Study NCT02339259 — intervention group
Intervention type: OTHER
Intervention: Observation
Study NCT03486509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: afatinb 40mg po bid
Study NCT03126604 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: female sexual function index
Description: evaluation of sexual functions questionnaire about Desire, Arousal, Orgasm,pain , lubrications, satisfactions
Study NCT02894099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolonged sitting time
Description: Volunteers will be continuously sitting on a chair for 5 hours and should move the least possible. If the participant needs to stand from the chair, the stage will be invalidated.
Study NCT02894099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PST+Light intensity Short bouts PA
Description: Volunteers will have their time sitting interrupted every 20 minutes for 2 minutes of physical activity of low intensity. In the active period, participants will be encouraged to walk in the hallway and reach a training heart rate between 50-60% HR max predicted for the age and measured by heart rate monitor. The Borg scale will be used at the beginning and the end of each active period in order to measure the subjective effort of the participants. In the end the volunteers will be sitting 5 hours and have 30 minutes (15 bouts of 2 minutes) of light intensity physical activity.
Study NCT02894099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PST+Moderate intensity Short bouts PA
Description: Volunteers will have their time sitting interrupted every 20 minutes for 2 minutes of physical activity of moderate intensity. In the active period, participants will be encouraged to walk in the hallway and reach a training heart rate between 65 a 75% HR max predicted for the age and measured by heart rate monitor. The Borg scale will be used at the beginning and the end of each active period in order to measure the subjective effort of the participants. In the end the volunteers will be sitting 5 hours and have 30 minutes (15 bouts of 2 minutes)of moderate intensity physical activity.